Mutual of America Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$432K Buy
10,714
+14
+0.1% +$523 ﹤0.01% 1098
2025
Q4
$372K Sell
10,700
-147,618
-93% -$11.6M ﹤0.01% 1138
2025
Q3
$13.2M Buy
158,318
+2,076
+1% +$150K 0.14% 126
2025
Q2
$11.5M Sell
156,242
-53,116
-25% -$3.85M 0.12% 153
2025
Q1
$23.9M Sell
209,358
-10,547
-5% -$642K 0.28% 42
2024
Q4
$11.1M Sell
219,905
-38,848
-15% -$2.04M 0.12% 145
2024
Q3
$12M Sell
258,753
-4,543
-2% -$161K 0.13% 135
2024
Q2
$8.55M Buy
263,296
+128,194
+95% +$3.51M 0.09% 202
2024
Q1
$3.4M Sell
135,102
-9,870
-7% -$233K 0.04% 669
2023
Q4
$4.71M Buy
144,972
+36,255
+33% +$996K 0.05% 478
2023
Q3
$2.96M Sell
108,717
-7,367
-6% -$213K 0.04% 678
2023
Q2
$2.58M Sell
116,084
-9,586
-8% -$221K 0.03% 801
2023
Q1
$2.72M Buy
125,670
+11,913
+10% +$261K 0.03% 772
2022
Q4
$2.31M Buy
113,757
+2,370
+2% +$59.4K 0.03% 843
2022
Q3
$2.86M Buy
111,387
+95,327
+594% +$2.55M 0.04% 686
2022
Q2
$382K Buy
16,060
+2,322
+17% +$50.6K ﹤0.01% 1153
2022
Q1
$309K Buy
13,738
+783
+6% +$16.7K ﹤0.01% 1209
2021
Q4
$257K Sell
12,955
-958
-7% -$19.4K ﹤0.01% 1279
2021
Q3
$274K Sell
13,913
-1,010
-7% -$21.1K ﹤0.01% 1253
2021
Q2
$328K Buy
14,923
+823
+6% +$18.3K ﹤0.01% 1250
2021
Q1
$335K Buy
14,100
+1,047
+8% +$28K ﹤0.01% 1227
2020
Q4
$341K Buy
13,053
+570
+5% +$12K ﹤0.01% 1170
2020
Q3
$217K Buy
12,483
+7,438
+147% +$119K ﹤0.01% 1209
2020
Q2
$85K Buy
5,045
+506
+11% +$7.11K ﹤0.01% 1211
2020
Q1
$54K Buy
4,539
+839
+23% +$10.4K ﹤0.01% 1269
2019
Q4
$45K Sell
3,700
-86
-2% -$1.2K ﹤0.01% 1373
2019
Q3
$54K Buy
3,786
+29
+0.8% +$356 ﹤0.01% 1320
2019
Q2
$42K Buy
3,757
+777
+26% +$8.66K ﹤0.01% 1382
2019
Q1
$35K Buy
2,980
+341
+13% +$4.24K ﹤0.01% 1378
2018
Q4
$35K Buy
2,639
+632
+31% +$8.35K ﹤0.01% 1320
2018
Q3
$28K Buy
2,007
+1,656
+472% +$23.1K ﹤0.01% 1389
2018
Q2
$6K Buy
+351
New +$6.11K ﹤0.01% 1332

Other funds holding CORT

Mutual of America Capital Management's CORT Position: Q1 2026 in Review

Mutual of America Capital Management increased its Corcept Therapeutics (CORT) stake by 0.13% in Q1 2026, buying an estimated $523 and bringing the position to 10,714 shares worth $432K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Mutual of America Capital Management first reported a position in CORT in Q2 2018 and has held it in 32 quarters since. The position peaked at $23.9M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Mutual of America Capital Management held 10,714 shares of Corcept Therapeutics worth $432K as of Q1 2026.
  • Mutual of America Capital Management bought 14 Corcept Therapeutics shares in Q1 2026, an estimated $523.
  • Corcept Therapeutics made up ﹤0.01% of Mutual of America Capital Management's portfolio in Q1 2026, its #1098 holding.
  • Mutual of America Capital Management first reported a position in Corcept Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Mutual of America Capital Management's Corcept Therapeutics position peaked at $23.9M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Mutual of America Capital Management's 13F filing for Q1 2026, filed 7 May 2026.